Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. Among authors: prica a. J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655. Online ahead of print. J Clin Oncol. 2024. PMID: 38531001
PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.
Lo AC, James LP, Prica A, Raymakers A, Peacock S, Qu M, Louie AV, Savage KJ, Sehn LH, Hodgson D, Yang JC, Eich HTT, Wirth A, Hunink MGM. Lo AC, et al. Among authors: prica a. J Nucl Med. 2022 Apr;63(4):543-548. doi: 10.2967/jnumed.121.262324. Epub 2021 Aug 19. J Nucl Med. 2022. PMID: 34413148 Free PMC article.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J. O'Connor OA, et al. Among authors: prica a. Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Lancet Oncol. 2018. PMID: 29276022 Free PMC article. Clinical Trial.
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
Jain MD, Lam R, Liu Z, Stubbins RJ, Kahlon A, Kansara R, Goswami R, Humar A, Prica A, Sehn LH, Slack GW, Crump M, Savage KJ, Peters AC, Kuruvilla J. Jain MD, et al. Among authors: prica a. Br J Haematol. 2020 Apr;189(1):97-105. doi: 10.1111/bjh.16304. Epub 2020 Feb 18. Br J Haematol. 2020. PMID: 32068243 Free article.
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
Yhim HY, Eshet Y, Metser U, Lajkosz K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Xu W, Rodin D, Hodgson D, Tsang R, Crump M, Kuruvilla J, Kridel R. Yhim HY, et al. Among authors: prica a. Am J Hematol. 2022 May;97(5):583-591. doi: 10.1002/ajh.26500. Epub 2022 Feb 23. Am J Hematol. 2022. PMID: 35170780 Free article.
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Vijenthira A, et al. Among authors: prica a. J Clin Oncol. 2023 Mar 10;41(8):1577-1589. doi: 10.1200/JCO.22.00478. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315922
Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial.
Puts M, Alqurini N, Strohschein F, Koneru R, Szumacher E, Mariano C, Monette J, Hsu T, Brennenstuhl S, McLean B, Wills A, Berger A, Amir E, Romanovsky L, Li A, Mehta R, Krzyzanowska M, Elser C, Jang R, Prica A, Wan-Chow-Wah D, Pitters E, Emmenegger U, Menjak IB, Bergman S, Lemonde M, Breunis H, Béland F, Alibhai SMH. Puts M, et al. Among authors: prica a. J Clin Oncol. 2023 Feb 1;41(4):847-858. doi: 10.1200/JCO.22.01007. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473126 Free PMC article.
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.
Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. Mikhael J, et al. Among authors: prica a. J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1. J Clin Oncol. 2019. PMID: 30932732
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R. Yhim HY, et al. Among authors: prica a. Blood Adv. 2020 Nov 24;4(22):5762-5771. doi: 10.1182/bloodadvances.2020002814. Blood Adv. 2020. PMID: 33216888 Free PMC article.
Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.
Cherniawsky H, Ting E, Zhang JZ, Xu W, Prica A, Bhella S, Yang C, Kridel R, Vijenthira A, Kukreti V, Crump M, Kuruvilla J. Cherniawsky H, et al. Among authors: prica a. Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):838-843. doi: 10.1016/j.clml.2023.07.012. Epub 2023 Jul 31. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37562990 Review.
100 results